Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review (Q33380863)

26 July 2017

1 reference

title

Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review (English)

1 reference

26 July 2017

1 reference

venous thromboembolism

1 reference

1

Elie A Akl

1 reference

26 July 2017

Irene Terrenato

5

0 references

Maddalena Barba

object named as

Maddalena Barba

series ordinal

3

0 references

Francesca Sperati

object named as

Francesca Sperati

series ordinal

4

0 references

Holger Jens Schünemann

series ordinal

8

object named as

Holger J Schünemann

1 reference

26 July 2017

6

Paola Muti

1 reference

26 July 2017

2

Sandeep Rohilla

1 reference

26 July 2017

7

Fadi Bdair

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 October 2008

1 reference

26 July 2017

number of pages

10

1 reference

inferred from page(s)

published in

Cancer

1 reference

26 July 2017

volume

113

1 reference

26 July 2017

issue

7

1 reference

26 July 2017

page(s)

1685-1694

1 reference

Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A meta-analysis of randomized, controlled trials

26 July 2017

cites work

1 reference

Low-molecular-weight heparin compared with intravenous unfractionated heparin for treatment of pulmonary embolism: a meta-analysis of randomized, controlled trials

21 January 2018

1 reference

Subcutaneous low-molecular-weight heparin compared with continuous intravenous heparin in the treatment of proximal-vein thrombosis

21 January 2018

1 reference

Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease

21 January 2018

1 reference

Treatment of acute venous thromboembolism with low molecular weight heparin (Fragmin). Results of a double-blind randomized study.

21 January 2018

1 reference

Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial

21 January 2018

1 reference

Fixed-dose, body weight-independent subcutaneous low molecular weight heparin Certoparin compared with adjusted-dose intravenous unfractionated heparin in patients with proximal deep venous thrombosis.

21 January 2018

1 reference

Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis

21 January 2018

1 reference

7 January 2021

Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.

1 reference

7 January 2021

A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency

1 reference

7 January 2021

Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: results of a meta-analysis

1 reference

7 January 2021

The statistical basis of meta-analysis

1 reference

7 January 2021

Comparison of subcutaneous low-molecular-weight heparin with intravenous standard heparin in proximal deep-vein thrombosis

1 reference

7 January 2021

Effects of a low-molecular-weight heparin on thrombus regression and recurrent thromboembolism in patients with deep-vein thrombosis

1 reference

7 January 2021

Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin

1 reference

7 January 2021

Subcutaneous adjusted-dose unfractionated heparin vs fixed-dose low-molecular-weight heparin in the initial treatment of venous thromboembolism

1 reference

7 January 2021

Low-molecular-weight heparin vs heparin in the treatment of patients with pulmonary embolism. American-Canadian Thrombosis Study Group

1 reference

7 January 2021

Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. The Tasman Study Group

1 reference

7 January 2021

A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis

1 reference

7 January 2021

A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire

1 reference

7 January 2021

Low-Molecular-Weight Heparin in the Treatment of Patients with Venous Thromboembolism

1 reference

7 January 2021

Comparison of low-molecular-weight heparin, administered primarily at home, with unfractionated heparin, administered in hospital, and subcutaneous heparin, administered at home for deep-vein thrombosis

1 reference

7 January 2021

A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis

1 reference

7 January 2021

Low-molecular-weight heparin vs unfractionated heparin for perioperative thromboprophylaxis in patients with cancer: a systematic review and meta-analysis

1 reference

7 January 2021

Low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism: meta-analysis of the randomized comparisons with oral anticoagulants.

1 reference

7 January 2021

Identifiers

DOI

10.1002/CNCR.23814

1 reference

26 July 2017

1 reference